An Oct. 12 research report noted that Infinity Pharmaceuticals Inc. (INFI:NASDAQ) announced "an IPI-549 late-breaking oral presentation" at the Society for Immunotherapy of Cancer's (SITC's) yearly conference next month."
The presentation will "describe new data for IPI-549, the orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase (PI3K) gamma," explained analyst Michael King Jr. with JMP Securities. The conference will be held Nov. 10-12 in National Harbor, Md.
That presentation is titled "Monotherapy dose escalation clinical and translational data from first-in-human study in advanced solid tumors of IPI-549, an oral, selective, PI3K-gamma inhibitor targeting tumor macrophages."
About the inclusion of Infinity as a presenter, King surmised, "The fact that it was chosen as one of 26 late breakers is suggestive of interesting activity for IPI-549."
Also, in a poster session at the SITC meeting, Infinity will "describe the ongoing Phase 1/1b clinical study exploring the safety and activity of IPI-549 both as a monotherapy and in combination with Opdivo, a PD-1 immune checkpoint inhibitor, in patients with advanced solid tumors," added King.
In the JMP report, the analyst also detailed catalysts expected this year for Infinity. With respect to the evaluation of IPI-549 as a monotherapy, it should start enrollment of patients with advanced solid tumors as an expansion cohort.
For the study of IPI-549 plus Opdivo, the company should complete the dose escalation phase and begin enrollment of an expansion cohort, comprised of patients with non-small cell lung cancer, melanoma and squamous cell carcinoma of the head and neck.
As for the biotech firm as an investment, King commented, "Infinity is a story driven by the clinical and commercial potential of its PI3K-gamma inhibitor rather than of earnings, in our view." However, given the "still early development stage of IPI-549, we remain on the sidelines. At present, we believe the market values the platform fairly, including assets currently in development."
JMP Securities has a Market Perform rating on Infinity.
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
JMP Securities, Infinity Pharmaceuticals Inc., Company Update, Oct. 12, 2017
Analyst Certification: The research analyst(s) who prepared this report does/do hereby certify that the views presented in this report are in accordance with my/our personal views on the securities and issuers discussed in this report. As mandated by SEC Regulation AC no part of my/our compensation was, is or will be directly or indirectly related to the specific views or recommendations expressed herein. This certification is made under the obligations set forth in SEC Regulation AC. Any other person or entity may not use it for any other purpose. This certification is made based on my/our analysis on the date of this report’s publication. I/We assume no obligation to update this certification to reflect any facts, circumstances or events that may subsequently come to my/our attention. Signed Michael G. King
JMP Securities Disclosures:
JMP Securities currently makes a market in the security of Infinity Pharmaceuticals, Inc.
JMP Securities expects to receive OR intends to seek compensation for investment banking services from Infinity Pharmaceuticals, Inc. in the next 3 months.
JMP Securities LLC (the “Firm”) compensates research analysts, like other Firm employees, based on the Firm’s profitability, which includes revenues from the Firm’s institutional sales, trading, and investment banking departments as well as on the quality of the services and activities performed that are intended to benefit the Firm’s institutional clients.
JMP Securities LLC, its affiliates, JMP Group LLC, Harvest Capital Strategies LLC, and their respective partners, directors, officers, and associates may have a long or short position in, may act as a market maker for, or may purchase or sell a position in the securities mentioned herein. JMP Securities LLC or its affiliates may be performing, have performed, or seek to perform investment banking, advisory, or other services and may have acted as manager or co-manager for a public offering of securities for any company mentioned herein. The reader should assume that JMP Securities LLC will solicit business from the company covered in this report.